Why Attovia Therapeutics, Inc.’s (ATTO) Stock Is Up 6.16%
As of Friday, September 18, Attovia Therapeutics, Inc.’s ATTO share price has surged by 6.16%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Stock Evaluator: Attovia Therapeutics, Inc. (ATTO)
Attovia Therapeutics, Inc. ATTO
$22.14
-0.59
-2.60%
September 18, 2026 4:00:00 PM
EST
Volume: 1,361,380
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn’s disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Commentary & Analysis
Why Attovia Therapeutics, Inc.’s (ATTO) Stock Is Up 6.43%
As of Thursday, September 17, Attovia Therapeutics, Inc.’s ATTO share price has surged by 6.43%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Attovia Therapeutics, Inc.’s (ATTO) Stock Is Up 6.19%
As of Monday, September 14, Attovia Therapeutics, Inc.’s ATTO share price has surged by 6.19%, which has investors questioning if this is right time to sell.Michael Rose
Why Attovia Therapeutics, Inc.’s (ATTO) Stock Is Up 5.55%
As of Friday, September 11, Attovia Therapeutics, Inc.’s ATTO share price has surged by 5.55%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Attovia Therapeutics, Inc.’s (ATTO) Stock Is Up 5.45%
As of Thursday, September 10, Attovia Therapeutics, Inc.’s ATTO share price has surged by 5.45%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ATTO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,010.7 | $269.5 | 45% |
|
| Shares Out (Mil) | 4.2 | 54.6 | 12% |
|
| Institutional Ownership | 82.6% | 92.9% | 51% |
|
| Float (Mil) | 26.3 | 42.3 | 33% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 356 | 593 | 52% |
|
| Price Change (52-week) |
na | 54.7% | na |
|
| Growth | ATTO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.0%) | na |
|
| EPS (5yr) | na | 15.4% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | ($0.500) | ($3.450) | ($2.380) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (89.8%) | (77.5%) | (83.9%) | |
| Financials | ATTO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $37 | 3% |
|
| Net Income (TTM) (Mil) | ($70) | ($43) | 14% |
|
| EPS (TTM) | ($17.010) | ($1.600) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($67) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $4 | $2 | 51% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $1,314 | $180 | 44% |
|
| Valuation | ATTO | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.66 | na |
|
| P/E | na | 19.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ATTO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (73.0%) | na |
|
| ROA | (109.7%) | (47.7%) | 5% |
|
| ROE | 96.8% | (54.9%) | 96% |
|
| Liabilities to Assets | 12.1% | 29.4% | 7% |
|
| F-Score | 1 | 2 | na |
|
Attovia Therapeutics, Inc. did not pass any screens on 9/18/2026.
